沙利魯單抗
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | IL-6R |
| 臨床資料 | |
| 商品名 | Kevzara |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617032 |
| 核准狀況 | |
| 給藥途徑 | 皮下注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物利用度 | 80% |
| 藥物代謝 | 可能是由蛋白酶 |
| 生物半衰期 | 21 天（預估，穩定態） |
| 識別資訊 | |
| CAS號 | 1189541-98-7  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6388H9918N1718O1998S44 |
| 摩爾質量 | 144,164.28 g·mol−1 |
沙利魯單抗（INN：Sarilumab）是治療類風濕性關節炎的藥物[5]。用於治療傳統治療無效的中度至重度疾病[5]。若無法取得托珠單抗時，也能用於治療重症2019冠狀病毒病 [6]。透過皮下注射給藥[5]。
最常見的副作用是感染[7]。其他副作用可能包括嗜中性白血球低下、血小板減少症、血脂異常、肝臟問題、過敏和癌症[7] [8]。注射部位可能會疼痛[5]。它是一種單株抗體，可與白細胞介素-6受體結合併阻斷其功能[5]。
沙利魯單抗於 2017 年在美國和歐洲取得醫療使用取可[8] [5]。
參考文獻
[編輯]- ^ Arthritis. Health Canada. 8 May 2018 [13 April 2024].
- ^ Regulatory Decision Summary for Kevzara. Drug and Health Products Portal. 12 January 2017 [13 April 2024].
- ^ Kevzara- sarilumab injection, solution. DailyMed. 17 June 2024 [26 August 2024].
- ^ Kevzara EPAR. European Medicines Agency (EMA). 23 June 2017 [26 August 2024].
- ^ 5.0 5.1 5.2 5.3 5.4 5.5 Kevzara. [11 October 2021]. （原始內容存檔於13 September 2021）.
- ^ Clinical Management Summary. COVID-19 Treatment Guidelines. [19 January 2022]. （原始內容存檔於5 November 2021） （英語）.
- ^ 7.0 7.1 Shagroni, T.; Cazares, Ramirez; Kim, J. A.; Furst, Daniel E. Katzung, Bertram G.; Trevor, Anthony J. , 編. 36. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout 15th. New York: McGraw-Hill. 2020: 678 [2021-11-06]. ISBN 978-1-260-45231-0. （原始內容存檔於2021-10-10） （英語）.
- ^ 8.0 8.1 Sarilumab Monograph for Professionals. Drugs.com. [11 October 2021]. （原始內容存檔於17 April 2021） （英語）.
延伸閱讀
[編輯]- Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A, Stevenson M. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (PDF). PharmacoEconomics. June 2018, 36 (12): 1427–1437. PMID 29882210. S2CID 46969760. doi:10.1007/s40273-018-0677-7.
- Genovese MC, van Adelsberg J, Fan C, Graham NM, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TW, van der Heijde D. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology. August 2018, 57 (8): 1423–1431. PMC 6055572
. PMID 29746672. doi:10.1093/rheumatology/key121. - McCarty D, Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease. March 2018, 10 (3): 61–67. PMC 5802641 . PMID 29492111. doi:10.1177/1759720X17752037.
- Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Design, Development and Therapy. 2017, 11: 1593–1603. PMC 5447699 . PMID 28579757. doi:10.2147/DDDT.S100302 .
